Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma

European Journal of Endocrinology

Volumn 157, Issue 2, 2007, Pages 215-220

  Frank Raue, Karin ^c   Fabel, Michael ^a   Delorme, Stefan ^a   Haberkorn, Uwe ^b   Raue, Friedhelm ^c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Department of Endocrine Practice ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; IMATINIB;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; MEDIASTINUM METASTASIS; NAUSEA; OPEN STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RASH; THYROID MEDULLARY CARCINOMA; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CALCITONIN; CARCINOMA, MEDULLARY; FEMALE; FLUORODEOXYGLUCOSE F18; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; SURVIVAL ANALYSIS; THYROID NEOPLASMS;

EID: 34547801152     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-06-0695     Document Type: Article

References (21)

1. Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA & Ponder BAJ. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Research 1996 56 2167-2170.
2. Schilling T, Bürck J, Sinn HP, Clemens A, Otto HF, Höppner W, Herfarth C, Ziegler R, Schwab M & Raue F. Prognostic value of codon 918 (ATG-ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. International Journal of Cancer 2001 95 62-66.
3. Machens A, Nicolli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B & Dralle H. Early malignant progression of hereditary medullary thyroid cancer. New England Journal of Medicine 2003 349 1517-1525.
4. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C & Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). British Journal of Cancer 2000 83 715-718.
5. de Groot JWB, Links TP, Plukker JTM, Lips CJM & Hofstra RMW. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumours. Endocrine Reviews 2006 27 535-560.
6. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S & Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine 2001 344 1031-1037.
7. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD & Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England Journal of Medicine 2002 347 472-480.
8. Krause DS & Van Etten RA. Tyrosine kinases as targets for thyroid cancer therapy. New England Journal of Medicine 2005 353 172-187.
9. Santoro M & Carlomagno F. Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nature Clinical Practice. Endocrinology & Metabolism 2006 2 42-52.
10. Cohen MS, Hussain HB & Moley JF. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 2002 132 960-966.
11. Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW & Nelkin BD. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2006 91 79-84.
12. de Groot JW, Plaza Menacho I, Schepers H, Drenth-Diephuis LJ, Osinga J, Plukker JT, Links TP, Eggen BJ & Hofstra RM. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia type 2A and 2B associated RET mutations. Surgery 2006 139 806-814.
13. Therasse P, Arbruck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC & Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 2000 92 205-216.
14. Weber WA, Ziegler SJ, Thödtmann R, Hanauske A-R & Schwaiger M. Reproducibility of metabolic measurements in malignant turnours using FDG PET. Journal of Nuclear Medicine 1999 40 1771-1777.
15. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J & Price P. Measurement of clinical and subclinical tumour response using 18F-fluorodeoxyglucose and position emission tomography: review and 1999 EORTC recommendations. EORTC PET Study Group. European Journal of Cancer 1999 35 1773-1782.
16. Cancer therapy evaluation program. Common toxicity criteria manual: common toxicity criteria, version 2.0. Bethesda, MD: National Cancer Institute, 1999. (Also available at http://ctep.cancer.gov/forms/ CTCManual-v4-10-4-99.pdf).
17. Frank-Raue K, Rondot S, Höppner W, Goretzki P, Raue F & Meng W. Coincidence of multiple endocrine neoplasia type 1 and 2: mutations in the RET proto-oncogene and MEN 1 tumor suppressor gene in a family presenting with recurrent primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2005 90 4063-4067.
18. Zonnenberg BA, Links T, Quarles van Uffort P, Lips C, De Groot J & Voest E. Phase-2 study of imatinib in metastasized medullary thyroid carcinoma. Journal of Clinical Oncology 2006 24 15550.
19. Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A & Slavin S. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocrine-Related Cancer 2006 13 535-540.
20. Savage DG & Antman KH. Imatinib mesylate - a new oral targeted therapy. New England Journal of Medicine 2002 346 683-693.
21. Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M & Santoro M. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004 23 6056-6063.